{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:13:55Z","timestamp":1780402435920,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12913-018-3020-2","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T10:53:45Z","timestamp":1524135225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"John W.","family":"Newcomer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9802-7660","authenticated-orcid":false,"given":"Daisy","family":"Ng-Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"3020_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J van Os","year":"2009","unstructured":"van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635\u201345.","journal-title":"Lancet"},{"key":"3020_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.161.1.1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1\u201356.","journal-title":"Am J Psychiatry"},{"key":"3020_CR3","unstructured":"National Alliance on Mental Illness. Schizophrenia Fact Sheet. 2015. https:\/\/www.nami.org\/NAMI\/media\/NAMI-Media\/Images\/FactSheets\/Schizophrenia-FS.pdf . Accessed 26 Apr 2017."},{"key":"3020_CR4","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. 5 edition. Washington, D.C: American Psychiatric Publishing; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"3020_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4088\/JCP.15m10278","volume":"77","author":"M Cloutier","year":"2016","unstructured":"Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77:764\u201371.","journal-title":"J Clin Psychiatry"},{"key":"3020_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.schres.2007.12.475","volume":"101","author":"S dosReis","year":"2008","unstructured":"dosReis S, Johnson E, Steinwachs D, Rohde C, Skinner EA, Fahey M, et al. Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia. Schizophr Res. 2008;101:304\u201311.","journal-title":"Schizophr Res"},{"key":"3020_CR7","first-page":"18","volume":"7","author":"K Fitch","year":"2014","unstructured":"Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits. 2014;7:18\u201326.","journal-title":"Am Health Drug Benefits"},{"key":"3020_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10597-012-9561-7","volume":"50","author":"S Abouzaid","year":"2014","unstructured":"Abouzaid S, Tian H, Zhou H, Kahler KH, Harris M, Kim E. Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia. Community Ment Health J. 2014;50:51\u20138.","journal-title":"Community Ment Health J"},{"key":"3020_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/1471-244X-13-246","volume":"13","author":"M Markowitz","year":"2013","unstructured":"Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry. 2013;13:246.","journal-title":"BMC Psychiatry"},{"key":"3020_CR10","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","volume":"55","author":"PJ Weiden","year":"2004","unstructured":"Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886\u201391.","journal-title":"Psychiatr Serv"},{"key":"3020_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz W, et al. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318\u201378.","journal-title":"World J Biol Psychiatry"},{"key":"3020_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"issue":"6","key":"3020_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","volume":"60","author":"JM Davis","year":"2003","unstructured":"Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 Jun;60(6):553\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"3020_CR14","doi-asserted-by":"crossref","unstructured":"Khasawneh FT, Shankar GS. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. In Cardiol Res Pract 2014. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3932258\/ . Accessed 28 Mar 2016.","DOI":"10.1155\/2014\/273060"},{"key":"3020_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4088\/JCP.v65n0219","volume":"65","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association. American Psychiatric Association, American Association of Clinical Endocrinologists, north American Association for the Study of obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267\u201372.","journal-title":"J Clin Psychiatry."},{"key":"3020_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.schres.2007.12.476","volume":"101","author":"KA Graham","year":"2008","unstructured":"Graham KA, Cho H, Brownley KA, Harp JB. Early treatment-related changed in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res. 2008;101:287\u201394.","journal-title":"Schizophr Res"},{"key":"3020_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","volume":"101","author":"JM Meyer","year":"2008","unstructured":"Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res. 2008;101:273\u201386.","journal-title":"Schizophr Res"},{"key":"3020_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RR, Perkins D, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med"},{"key":"3020_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy J, Swartz M, Davis SM, Rosenheck RR, et al. Effectiveness of olanzapine, quetiapine, risperidone, and Zziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611\u201322.","journal-title":"Am J Psychiatry"},{"key":"3020_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","volume":"163","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer H, Rosenheck RR, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600\u201310.","journal-title":"Am J Psychiatry"},{"key":"3020_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","volume":"107","author":"TS Stroup","year":"2009","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe R, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res. 2009;107:1\u201312.","journal-title":"Schizophr Res"},{"key":"3020_CR22","unstructured":"Latuda Prescribing Information. 2017. http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf . Accessed 14 Apr 2017."},{"key":"3020_CR23","unstructured":"Seroquel Prescribing Information. 2016. http:\/\/www.azpicentral.com\/seroquel\/seroquel.pdf ."},{"key":"3020_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","volume":"147","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147:95\u2013102.","journal-title":"Schizophr Res"},{"key":"3020_CR25","unstructured":"US Department of Health & Human services. Who is eligible for Medicaid? 2015. http:\/\/www.hhs.gov\/answers\/medicare-and-medicaid\/who-is-eligible-for-medicaid\/index.html . Accessed 09 Nov 2016."},{"key":"3020_CR26","unstructured":"United States Congress. Patient Protection and Affordable Care Act [Internet]. Sect. 3025, 111\u2013148 Mar 23, 2010. Available from: http:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-111publ148\/pdf\/PLAW-111publ148.pdf"},{"key":"3020_CR27","unstructured":"US Bureau of Labor Statistics. Measuring price change for medical care in the CPI. 2010. http:\/\/www.bls.gov\/cpi\/cpifact4.htm#1a . Accessed 27 Mar 2017."},{"key":"3020_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/j.1742-1241.2006.01161.x","volume":"60","author":"F Gianfrancesco","year":"2006","unstructured":"Gianfrancesco F, Wang RH, Pesa J, Rajagopalan K. Hospitalisation risks in the treatment of schizophrenia in a Medicaid population: comparison of antipsychotic medications. Int J Clin Pract. 2006;60:1419\u201324.","journal-title":"Int J Clin Pract"},{"key":"3020_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/hec.1653","volume":"20","author":"B Mihaylova","year":"2011","unstructured":"Mihaylova B, Briggs A, O\u2019Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897\u2013916.","journal-title":"Health Econ"},{"key":"3020_CR30","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1185\/03007995.2010.515900","volume":"26","author":"H Ascher-Svanum","year":"2010","unstructured":"Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, et al. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin. 2010;26:2403\u201310.","journal-title":"Curr Med Res Opin"},{"key":"3020_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","volume":"164","author":"TS Stroup","year":"2007","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007;164:415.","journal-title":"Am J Psychiatry"},{"key":"3020_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/schbul\/sbm061","volume":"34","author":"SC Marcus","year":"2008","unstructured":"Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34:173\u201380.","journal-title":"Schizophr Bull"},{"key":"3020_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/schbul\/sbm134","volume":"34","author":"H Ascher-Svanum","year":"2008","unstructured":"Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34:1163\u201371.","journal-title":"Schizophr Bull"},{"key":"3020_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200422010-00001","volume":"22","author":"SL Tunis","year":"2004","unstructured":"Tunis SL, Ascher-Svanum H, Stensland M, Kinon BJ. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. PharmacoEconomics. 2004;22:1\u20138.","journal-title":"PharmacoEconomics"},{"key":"3020_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","volume":"17","author":"JM Haro","year":"2007","unstructured":"Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17:235\u201344.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3020_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1017\/S1092852915000917","volume":"21","author":"C Correll","year":"2016","unstructured":"Correll C, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectrums. 2016;21:383\u2013402.","journal-title":"CNS Spectrums"},{"key":"3020_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","volume":"30","author":"M Valenstein","year":"2004","unstructured":"Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30:255.","journal-title":"Schizophr Bull"},{"key":"3020_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2147\/nedt.2007.3.2.277","volume":"3","author":"XS Ren","year":"2007","unstructured":"Ren XS, Qian S, Kazis LE. An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the veterans health administration. Neuropsychiatr Dis Treat. 2007;3:277\u201384.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3020_CR39","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1176\/appi.ps.201100402","volume":"63","author":"M Stensland","year":"2012","unstructured":"Stensland M, Watson PR, Grazier KL. An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals. Psychiatr Serv Wash DC. 2012;63:666\u201371.","journal-title":"Psychiatr Serv Wash DC"},{"key":"3020_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10488-010-0310-3","volume":"38","author":"AD Tulloch","year":"2011","unstructured":"Tulloch AD, Fearon P, David AS. Length of stay of general psychiatric inpatients in the United States: systematic review. Adm Policy Ment Health Ment Health Serv Res. 2011;38:155\u201368.","journal-title":"Adm Policy Ment Health Ment Health Serv Res"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-018-3020-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3020-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T01:49:56Z","timestamp":1571190596000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-018-3020-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3020"],"URL":"https:\/\/doi.org\/10.1186\/s12913-018-3020-2","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"assertion":[{"value":"28 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study data were de-identified according to the Health Insurance Portability and Accountability Act (HIPAA) of 1996, and therefore the study did not require approval or waiver from an institutional review board. Data access was provided based on a licensing agreement between Truven Health Analytics LLC and Sunovion Pharmaceuticals Inc and data analysis was provided by Truven Health Analytics LLC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author JN is an unpaid consultant of Sunovion Pharmaceuticals Inc. NG, KR, and AL are employees of Sunovion Pharmaceuticals Inc. The authors attest that all financial or other relationships that could be construed as a conflict of interest, and that all sources of financial support for this study, have been disclosed as indicated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"243"}}